NeoGenomics 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- NeoGenomics reported second quarter 2026 total revenue of $201.7 million, up 11% year over year and exceeding guidance by approximately $4 million.
- Clinical revenue grew 14% year over year, driven by a 2% increase in test volumes and a 12% increase in average unit price (AUP).
- Next-generation sequencing (NGS) revenue grew 26% year over year, comprising one-third of clinical revenue, with large NGS panels growing above 20%.
- Non-clinical revenue declined 15% year over year, with pharma revenue down 26%, partially offset by 17% growth in oncology data solutions.
- Adjusted gross margin expanded by approximately 260 basis points to 48.1%, driven by volume growth, pricing gains, and lab of the future efficiencies.
- Adjusted EBITDA increased 36% year over year to $14.4 million, reflecting revenue growth and operating expense discipline.
- NeoGenomics raised $316 million via convertible senior notes due 2032 and retired $276 million of notes due 2028, strengthening capital structure.
- The company invested $8 million in capital expenditures, including transitioning the liquid biopsy assay to the Novaseq X platform.
- NeoGenomics settled a legacy DOJ matter with a $10 million payment, impacting third quarter cash from operations.
- The commercial organization was reorganized into two dedicated ecosystems for oncology and pathology, each with about 60+ sales representatives.
- The Pan Tracer family and Radar Street products address a combined $33 billion market opportunity in therapy selection and minimal residual disease (MRD).
- Radar Street has two Medicare-reimbursed indications with three additional submissions pending; reimbursement decisions are key to future revenue growth.
- NeoGenomics continues to invest in pipeline development, including a next-generation whole genome sequencing MRD assay expected to generate data in 2027 and potential launch in 2029.
- The company launched PTEN, an FDA-approved companion diagnostic for prostate cancer, expanding into urologic oncology.
- Customer experience remains strong with a Net Promoter Score in the high 70s across pathology and oncology.
- NeoGenomics exited a high volume, low value contract that peaked in Q3 2025, affecting volume growth comparisons in 2026.
- Pharma bookings increased significantly in Q2 2026, but revenue pull-through lagged, leading to lowered pharma revenue expectations for the full year.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, welcome to the NeoGenomics second quarter 2026 financial results call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I will now turn the call over to Abhishek Jain, Chief Financial Officer.
Before we begin, I would like to introduce Andrew Brackman, who recently joined NeoGenomics as our new Vice President of Investor Relations. Andrew spent nearly a decade in sell-side equity research covering the diagnostic sector. He also covered NeoGenomics directly, giving him a deep understanding of both the company and its competitive landscape. Beyond his analytical depth, Andrew is known for building genuine, long-term relationships with the people he works with. We're excited to have Andrew on board to lead and shape our investor relation strategy and deepen our relationships across the investor and analyst community. Let me turn the call over to Andrew to get us started.
Andrew? Thank you, Abhishek, good afternoon, everyone.
I am excited to be joining NeoGenomics in this role. Having covered the stock for the last eight years during my time at William Blair, I have been inspired by the team's ability to leverage its well-earned channel strength and provide new and holistic testing solutions for patients. I see this strategy as driving durable, profitable growth that betters Neo over the long term for all stakeholders. With recent new product launches further expanding growth opportunities across large end markets, now is a great time to join the company. In this role, it is my goal to partner with the investment community in an ongoing effort to better articulate and communicate our strategy and differentiation. This is something I believe to be a real opportunity to improve upon based on my experience on the sell side.
I am confident my skill set and experience across the financial markets will be helpful in this regard. Let's get into today's call. Representing NeoGenomics here today are Tony Zook, Chief Executive Officer, Warren Stone, President and Chief Commercial Officer, and Abhishek Jain, Chief Financial Officer. Additional members of the management team will be available for the Q&A portion of our call. This call is being simultaneously webcast. During this call, we will make forward-looking statements regarding our future financial and business performance, planned future operations, and related expectations with respect to timing and performance, future financial position, future revenues, growth potential, and expected growth drivers, projected costs and capital expenditures, prospects and plans, estimates of market size and position, and objectives of management and financial guidance. We caution you that the actual events or results could differ materially from those expressed or implied by the forward-looking statement.
These forward-looking statements made during this call speak only as of the original date of this call, and we undertake no obligation to update or revise any of these statements. Please refer to the information disclosed on the safe harbor statement slide in the deck posted on our website, as well as the information under the heading Risk Factors in our most recent Forms 10-K, 10-Q, and 8-K that were filed with the SEC to identify important risks or other factors that may cause our actual results to differ materially from the forward-looking statements. These documents can be found in the investor section of our website or on the SEC's website. During this call, we will also refer to certain non-GAAP financial measures that involve adjustments to GAAP results.
The non-GAAP financial measures presented should not be considered an alternative to the financial measures required by GAAP, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measures in a table available in the press release we issued this afternoon and in the slide deck available in the investors section of our website. I will now turn the call over to Tony.
Well, thank you, Andrew, and welcome to the team. We're very pleased to have you join us. Good afternoon, everyone. At NeoGenomics, our leading 25% market share across hematology diagnostics and therapy selection make us a trusted provider of oncology testing solutions for pathologists, oncologists, and patients. We're leveraging this leadership position as a trusted partner in hematology by expanding our menu of solid tumor testing offerings in the large, under-penetrated markets of therapy selection and MRD, where we've recently launched new products, expanding our PanTracer family and RaDaR ST. Our entry into these markets is driving growth across our entire NGS business while providing halo effects to the rest of our portfolio. They're also helping to drive increases in our gross margin.
In the second quarter, our strategy drove this intended effect, and we remain confident in our objective of driving durable and profitable growth over the near and long term. As it relates to the second quarter results, these reflect the consistency that investors have come to expect from this team. We're raising guidance because of these results, as well as the underlying clinical strength we're seeing in the back half of this year. Total revenue in the quarter was $201.7 million, up 11% year-over-year and ahead of the 9% growth we guided to for the quarter. Our top-line performance continues to be driven by our clinical business, which grew by 14% in the quarter as AUP increased 12% and volume exceeded our target and grew 2%.
Moreover, our growth in NGS is proving to be durable, with revenue growing 26% year-over-year, and again, comprising a third of our clinical revenue. The mix shift towards higher value testing continues, and we believe our NGS portfolio is well-positioned to drive more predictable and profitable revenue growth in the future. Alongside this growth, our go-to-market approach continues to evolve as well. This quarter, we reorganized our commercial team into two dedicated ecosystems, one focused on oncology and one on pathology. Sharpening accountability as we scale towards our next phase of growth. Warren will cover this in more detail shortly. While the 14% growth in our clinical business is exceeding our expectations, our non-clinical business is falling short of expectations. In particular, our pharma business, which accounts for roughly 5% of total revenue, continues to face headwinds even as bookings increase.
The decline in pharma was slightly offset by 17% growth in our ODS business, but still not enough to offset the weakness for our entire non-clinical business. We're adjusting expectations for pharma revenues for the full year. Abhishek will cover the specifics, but we're taking corrective actions and remain committed to returning to year-over-year growth for our entire non-clinical segment in 2027, as we've discussed in the past. Turning to margins, we saw significant margin improvement this quarter, as we anticipated. Adjusted gross margin expansion of 260 basis points year-over-year was driven primarily by strong AUP growth of 12%, as well as improvements from our Lab of the Future initiative, which spans across automation, digital pathology, and instrument upgrades, among other initiatives. Warren will discuss our Lab of the Future initiative in more detail momentarily.
Beyond the gross margin expansion, we also maintained operating expenses discipline in the quarter, helping to drive 36% growth in our adjusted EBITDA. On the product front, this quarter was less about new launches and more about converting the launches we discussed last quarter into real commercial traction. Our PanTracer family and RaDaR ST together address a combined $33 billion market opportunity across therapy selection and MRD, and round out a portfolio that spans the cancer care continuum from initial diagnosis through recurrence monitoring. Early feedback for these products is encouraging, and our expectations for these products in 2026 are unchanged, contributing modestly to revenue this year while driving pull-through in other areas of our portfolio. This is something unique to NeoGenomics, as we have the capabilities and menu that other pure play NGS providers don't have.
As we look ahead, we continue to see more meaningful contribution from these specific products over the coming years. This is especially true for RaDaR ST, where reimbursement decisions will be key to driving future revenue. In the quarter, we submitted an additional RaDaR ST indication to MolDx and now have three pending submissions. If successful in achieving these reimbursement wins, as well as with commercial payers over the longer term, these reimbursement wins will significantly improve our ability to drive revenue in this large market. Beyond the commercial traction we're seeing across our portfolio, we continue to invest in the pipeline that will sustain our growth well beyond 2026. Notably, our next generation whole genome sequencing MRD assay remains on track, and we expect to generate data for this assay in 2027 and be ready for a potential clinical launch in 2029.
Our companion diagnostics capabilities were strengthened with the recent launch of PTEN, a new FDA-approved immunohistochemistry companion diagnostic for prostate cancer. This test, which is available standalone or as part of our PanTracer Pro offering, identifies patients who may be eligible for AstraZeneca's newly approved TRUQAP and allows us to reach into urologic oncology, a new setting for us. For our pharma and biopharma partners, work continued in the second quarter with new biomarker data presented at ASCO, supporting our partners who are advancing ADCs, bites, bispecifics, and targeted therapies. We're also developing a low sample input AML MRD flow assay designed to deliver higher sensitivity and faster turnaround times across CLL, B-ALL, and multiple myeloma. In sum, the second quarter builds on many of the favorable trends we saw in the first. Steady top-line growth, expanding margins, and continued scientific and pipeline progress against our 2026 priorities.
Perhaps more important is that we're delivering consistent results which underpin our confidence in our updated guidance ranges. We remain in the early stages of penetrating the solid tumor therapy selection and MRD markets, and the groundwork we're laying now in our science, our lab operations, and our product portfolio positions us well for the years ahead. With that, I'll turn the call over to Warren, who'll provide more detail on how we continue to win in the community and on the progress of our commercial and operational initiatives this quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
